A Study of ART105 in Healthy Adult Participants

Inclusion criteria

• Voluntary participation with signed written informed consent (ICF) .
• Male or female, aged 18-55 years (inclusive).
• males ≥ 50 kg; females ≥ 45 kg; and BMI between 19 and 26 kg/m² (inclusive).
• No history of clinically significant abnormalities.
• Normal or not clinically significant (NCS) findings at screening for vital signs, physical exam, lab tests, 12-lead ECG, and abdominal ultrasound.
• Participants of childbearing potential (or males with partners of childbearing potential) must agree to use highly effective contraception.

Exclusion criteria

• Any uncontrolled or severe disease, or any medical or surgical condition that may interfere with the participant's participation in the clinical trial
• History of hypersensitivity to oligonucleotide drugs, or known hypersensitivity to the investigational product or any of its excipients
• Use of any ASO or siRNA drugs within 12 months prior to the first dose
• History of alcohol abuse
• History of drug or substance abuse, or a positive urine drug abuse screening test
• Major surgery within 3 months prior to the administration of the investigational product or planned elective surgery during the study period.
• Use of any prescription medications, over-the-counter (OTC) drugs, or herbal medicines within 14 days prior to the administration of the investigational product, or within 5 half-lives of the drug (whichever is longer).
• Enrollment in or ongoing participation in any other clinical trial within 3 months or 5 half-lives (whichever is longer) prior to the administration of the investigational product
• Positive screening results for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (anti-HCV), human immunodeficiency virus antibody (anti-HIV), or Treponema pallidum antibody (syphilis).
• Occurrence of acute illness or use of concomitant medications from the screening phase until prior to the administration of the investigational product.
• Consumption of any alcohol-containing products or a positive breath alcohol test within 48 hours prior to the administration of the investigational product.
• Participants who, in the investigator's opinion, have other factors that make them unsuitable for participation in this study.